The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Open accessAbstract
Purpose: Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope. We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients. Patients and Methods: In this open-label trial, 1,113 patients, predominantly younger than age 60 years, were randomly assigned to receive a single dose of GO (3 mg/m 2) on day 1 of induction course 1 with one of the following three induction schedules: daunorubicin and cytarabine; cytarabine, daunorubicin, and etoposide; or fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin. In remission, 948 patients were randomly assigned to GO in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine. The primary end points were response rate and survival. Results: The addition of GO was well tolerated with no significant increase in toxicity. There was no overall difference in response or survival in either induction of consolidation. However, a predefined analysis by cytogenetics showed highly significant interaction with induction GO (P = .001), with significant survival benefit for patients with favorable cytogenetics, no benefit for patients with poor-risk disease, and a trend for benefit in intermediate-risk patients. An internally validated prognostic index identified approximately 70% of patients with a predicted benefit of 10% in 5-year survival. Conclusion: A substantial proportion of younger patients with AML have improved survival with the addition of GO to induction chemotherapy with little additional toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Döhner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rücker, F. G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., & for the AML Study Group (AMLSG) (2005) · Blood · doi:10.1182/blood-2005-05-2164 · Cited by 849
Gale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K., & Linch, D. C. (2008) · Blood · doi:10.1182/blood-2007-08-109090 · Cited by 745
Self-citationPaschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
Schnittger, S., Kohl, T. M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K., & Schoch, C. (2006) · Blood · doi:10.1182/blood-2005-04-1466 · Cited by 380
Taussig, D. C. (2005) · Blood · doi:10.1182/blood-2005-03-1072 · Cited by 370
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., Alyea, E. P., Antin, J. H., Stone, R. M., Soiffer, R. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0255 · Cited by 323
Care, R. S., Valk, P. J. M., Goodeve, A. C., Abu‐Duhier, F. M., Geertsma‐Kleinekoort, W. M. C., Wilson, G. A., Gari, M. A., Peake, I. R., Löwenberg, B., & Reilly, J. T. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04362.x · Cited by 323
Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia-Manero, G., Waddelow, T. A., David, C. L., Phan, A. T., Colburn, D. E., Rashid, A., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u · Cited by 283
Green, C. L., Koo, K. K., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2501 · Cited by 273
Self-citationFeldman, E. J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G. J., Miller, C., Chopra, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.133 · Cited by 249
Burnett, A. K., Hills, R. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Duncombe, A. S., Gibson, B. E. S., & Wheatley, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9088 · Cited by 230
Self-citationLarson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Virappane, P., Gale, R., Hills, R., Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0333 · Cited by 218
Self-citationWalter, R. B., Gooley, T. A., van der Velden, V. H. J., Loken, M. R., van Dongen, J. J. M., Flowers, D. A., Bernstein, I. D., & Appelbaum, F. R. (2007) · Blood · doi:10.1182/blood-2006-09-047399 · Cited by 195
Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., et al. (2009) · Blood · doi:10.1182/blood.v114.22.790.790 · Cited by 184
Caron, P., Jurcic, J., Scott, A., Finn, R., Divgi, C., Graham, M., Jureidini, I., Sgouros, G., Tyson, D., & Old, L. (1994) · Blood · doi:10.1182/blood.v83.7.1760.1760 · Cited by 181
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., Ma, Y., Moore, R., Mungall, A. J., Marra, M. A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4439 · Cited by 848
Metadata
- Authors
- Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-01
- Volume
- 29
- Issue
- 4
- Pages
- 369-377
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127568389
- Cited by
- 657
- References
- 24
- FWCI
- 33.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.